Abeona Therapeutics Inc (NASDAQ:ABEO - Free Report) - Investment analysts at HC Wainwright decreased their Q2 2025 earnings per share (EPS) estimates for Abeona Therapeutics in a report released on Wednesday, April 30th. HC Wainwright analyst R. Selvaraju now anticipates that the biopharmaceutical company will post earnings per share of ($0.37) for the quarter, down from their prior forecast of ($0.36). HC Wainwright currently has a "Buy" rating and a $20.00 target price on the stock. The consensus estimate for Abeona Therapeutics' current full-year earnings is ($1.16) per share. HC Wainwright also issued estimates for Abeona Therapeutics' Q3 2025 earnings at ($0.18) EPS, Q4 2025 earnings at $0.04 EPS, FY2025 earnings at ($0.83) EPS, Q1 2026 earnings at $0.10 EPS, Q2 2026 earnings at $0.11 EPS, Q3 2026 earnings at $0.16 EPS, Q4 2026 earnings at $0.19 EPS and FY2026 earnings at $0.57 EPS.
ABEO has been the topic of a number of other research reports. StockNews.com upgraded Abeona Therapeutics from a "sell" rating to a "hold" rating in a research report on Monday, March 24th. Oppenheimer assumed coverage on Abeona Therapeutics in a research report on Wednesday, March 5th. They issued an "outperform" rating and a $16.00 price objective on the stock. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $18.75.
Read Our Latest Research Report on ABEO
Abeona Therapeutics Price Performance
Shares of NASDAQ ABEO traded down $0.40 during midday trading on Friday, hitting $5.37. 842,969 shares of the company's stock were exchanged, compared to its average volume of 566,449. Abeona Therapeutics has a 12-month low of $3.93 and a 12-month high of $7.32. The company has a market cap of $261.81 million, a price-to-earnings ratio of -1.99 and a beta of 1.68. The company has a current ratio of 6.12, a quick ratio of 6.12 and a debt-to-equity ratio of 0.31. The business's fifty day moving average price is $5.12 and its two-hundred day moving average price is $5.60.
Abeona Therapeutics (NASDAQ:ABEO - Get Free Report) last announced its quarterly earnings results on Thursday, March 20th. The biopharmaceutical company reported ($0.24) EPS for the quarter, beating the consensus estimate of ($0.43) by $0.19.
Insider Buying and Selling
In related news, CEO Vishwas Seshadri sold 25,000 shares of the firm's stock in a transaction that occurred on Monday, March 31st. The shares were sold at an average price of $4.78, for a total transaction of $119,500.00. Following the completion of the sale, the chief executive officer now owns 1,355,322 shares of the company's stock, valued at $6,478,439.16. This trade represents a 1.81 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 5.40% of the stock is currently owned by company insiders.
Institutional Trading of Abeona Therapeutics
Institutional investors have recently added to or reduced their stakes in the business. Twinbeech Capital LP purchased a new stake in shares of Abeona Therapeutics during the fourth quarter valued at $58,000. Squarepoint Ops LLC bought a new stake in shares of Abeona Therapeutics in the fourth quarter worth approximately $67,000. Cannon Global Investment Management LLC purchased a new position in shares of Abeona Therapeutics during the first quarter valued at approximately $67,000. Jane Street Group LLC purchased a new stake in Abeona Therapeutics in the third quarter worth approximately $84,000. Finally, Oxford Asset Management LLP bought a new stake in Abeona Therapeutics in the 4th quarter worth approximately $118,000. 80.56% of the stock is currently owned by hedge funds and other institutional investors.
About Abeona Therapeutics
(
Get Free Report)
Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.
Featured Articles
Before you consider Abeona Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Abeona Therapeutics wasn't on the list.
While Abeona Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
